Boston Scientific (NYSE:BSX) Director Edward Ludwig Purchases 5,000 Shares

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig acquired 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Boston Scientific Stock Performance

Boston Scientific stock opened at $48.45 on Tuesday. The firm has a market capitalization of $72.02 billion, a P/E ratio of 19.62, a PEG ratio of 1.02 and a beta of 0.56. The stock has a fifty day moving average price of $45.95 and a 200 day moving average price of $61.70. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has approved a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. purchased a new position in Boston Scientific in the second quarter valued at approximately $1,079,000. Mill Capital Management LLC purchased a new stake in Boston Scientific during the second quarter worth approximately $9,851,000. Cary Street Partners Financial LLC grew its stake in Boston Scientific by 16.7% during the second quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock worth $1,071,000 after buying an additional 3,597 shares during the period. Farther Finance Advisors LLC increased its position in shares of Boston Scientific by 28.9% in the second quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock worth $1,227,000 after acquiring an additional 6,427 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in shares of Boston Scientific by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock worth $2,106,000 after acquiring an additional 1,119 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. UBS Group decreased their target price on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a research note on Thursday. Truist Financial decreased their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.